Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06136195
Other study ID # 2000029675
Secondary ID 2P50AA012870-21
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date July 1, 2024
Est. completion date May 31, 2026

Study information

Verified date March 2024
Source Yale University
Contact Suchitra Krishnan, PhD
Phone 203-974-7595
Email suchitra.krishnan-sarin@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to find out about the effects of a drug called mavoglurant on alcohol consumption.


Description:

This project will use a double-blind, placebo-controlled, within-subject design to examine mavoglurant effects on alcohol craving, drinking, and subjective responses. Non-treatment seeking, heavy drinkers with Alcohol Use Disorder (AUD) will undergo 2 lab sessions, which include a Cue Exposure (craving) Paradigm (CEP) and an Alcohol Drinking Paradigm (ADP), as well as 1-week and 1-month follow up appointments. Prior to the first lab session, participants will be randomized to receive either 200 mg of mavoglurant or placebo. For the second lab session, participants will receive the other condition, mavoglurant or placebo, that they did not receive in the first lab session. Each session will be separated by at least a 5-8 day washout period to allow for complete washout of mavoglurant. This is followed by 1-week and 1-month follow up appointments.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 63
Est. completion date May 31, 2026
Est. primary completion date May 31, 2026
Accepts healthy volunteers No
Gender All
Age group 21 Years to 50 Years
Eligibility Inclusion Criteria: 1. Ages 21-50 (The lower limit is to avoid offering alcohol to individuals below the drinking age of 21. The upper age is determined by experience recruiting for our prior studies). 2. Ability to read English at 6th grade level or higher. 3. Meet DSM-V criteria for moderate or severe Alcohol Use Disorder (AUD). 4. Average weekly alcohol consumption of 30-70 standard drinks for men and 20-65 drinks for women. The lower limits are consistent with the lower sex-specific cut-offs defining high-risk drinking based on World Health Organization Risk Levels (WHO, 2000); the upper limits are designed to avoid recruiting participants whose drinking is likely to exceed the number of drinks available in the Alcohol Drinking Paradigm (ADP). Exclusion Criteria: 1. Individuals who are seeking alcohol treatment or have been in alcohol treatment within the past 6 months. 2. Meet current Diagnostic and Statistical Manual v.5 (DSM-V) criteria for substance use disorder, except for tobacco use disorder or mild cannabis use disorder. 3. Positive urine drug screens at more than 1 baseline appointment for opiates, cocaine, benzodiazepines and barbiturates. 4. Psychotic or other severe psychiatric disorders as determined by clinical evaluation (Structured Clinical Interview for DSM-V; SCID). Note that if a subject endorses any harm/risk behaviors (e.g. suicidal/homicidal risk) a licensed clinician will be consulted immediately. 5. Regular use of psychoactive drugs, except for individuals on a stable dose of an antidepressant for at least 2 months. 6. Medical conditions that would contraindicate the consumption of alcohol or use of mavoglurant. 7. Clinically significant abnormalities in screening laboratories, including aspartate aminotransferase (AST) >3 times upper limit of normal (ULN); alanine aminotransferase (ALT) > 3 times ULN; total bilirubin >1.5 times ULN; serum creatinine >2.0 times ULN. 8. Neurological trauma or disease, delirium or hallucinations, or clinically significant or unstable medical conditions, including uncontrolled hypertension or diabetes, or significant cardiac, pulmonary, renal, hepatic, endocrine, or other systemic diseases, which in the opinion of the study physician and Principal Investigator, may put the patient at risk because of participation in the study. 9. Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar) scores of 8 or greater or a history of significant repeated alcohol withdrawals to reduce the likelihood of withdrawal symptomatology if subjects reduce their drinking. 10. Women who are pregnant or nursing. 11. Participants who refuse to use a reliable method of birth control. 12. Subjects who report disliking spirits will be excluded because hard liquor will be provided during the ADP. 13. Subjects who have taken any investigational drug within 4 weeks of the anticipated date of the first study dose. 14. Individuals who report heavy drinking days in the 2 days prior to their intake appointment but have a negative ethyl glucuronide (EtG) test to rule out subjects who are misrepresenting their drinking history. 15. Subjects who have donated blood within the past 6 weeks.

Study Design


Intervention

Drug:
Mavoglurant
The 200mg mavoglurant will be administered in the form of two 100mg oral tablets. Placebo will be administered with matching tablets.

Locations

Country Name City State
United States Yale New Haven Hospital New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in the number of drinks consumed The number of drinks consumed during the adlib session will be recorded Lab Session 1 (Day 1); Lab Session 2 (5-8 days after Lab Session 1).
Primary Change in craving for alcohol The Cue Exposure Paradigm (CEP) is used to measure craving for alcohol. The task uses a questionnaire that is in the form of a Visual Analog Scale (VAS). The endpoints will be marked with a 0 on the left indicating no craving and a 20 on the right indicating severe craving. Participants will indicate how strong they are craving to drink alcohol. The VAS takes 2-3 minutes to complete. Lab Session 1 (Day 1); Lab Session 2 (5-8 days after Lab Session 1).
See also
  Status Clinical Trial Phase
Completed NCT05037630 - Feasibility Evaluation of a Self-guided Digital Tool for Problematic Alcohol Use N/A
Completed NCT03037749 - Over-arousal as a Mechanism Between Alcohol and Intimate Partner Violence N/A
Enrolling by invitation NCT02927132 - Guilt and Expressive Writing for Reducing Alcohol Use in College Students N/A
Completed NCT02905123 - Brief Internet Intervention for Hazardous Alcohol Use N/A
Enrolling by invitation NCT02952495 - Online Education to Inform the Elderly About Age-related Alcohol Risks Phase 2
Completed NCT01923246 - Development of IVR and WEB Alcohol Interventions N/A
Completed NCT01129804 - Network Support for Alcohol Treatment 2 N/A
Completed NCT00374153 - Southern Methodist Alcohol Research Trial (SMART) N/A
Completed NCT01126164 - Parent Intervention to Reduce Binge Drinking N/A
Completed NCT00383838 - Self-Selected Brief Alcohol Intervention for Adolescents N/A
Completed NCT03408743 - Engineering an Online STI Prevention Program: CSE2 N/A
Recruiting NCT04957628 - AlcoTail - Implementation of Tailored Interventions
Recruiting NCT04164940 - Patient Trajectories for Older Adults Admitted to Hospital for Alcohol-related Problems
Completed NCT00292240 - Brief Youth Substance Use Intervention for Primary Care N/A
Completed NCT04804579 - Boston ARCH 4F Intervention to Reduce Fall Risk in People With HIV and Alcohol Use N/A
Completed NCT02387489 - A Clinical Trial of SBIRT Services in School-based Health Centers N/A
Completed NCT02188446 - Intensive Smoking and Alcohol Cessation Intervention in Bladder Cancer Surgery Patients N/A
Completed NCT01688245 - A Text Message Behavioral Intervention to Reduce Alcohol Consumption in Young Adults N/A
Withdrawn NCT01739842 - Kudzu Effects on Brain Ethanol Levels: Proton Spectroscopy Assessment Phase 2/Phase 3
Completed NCT00561587 - Quetiapine vs. Placebo in Alcohol Relapse Prevention - a Pilot Study Phase 2